Abstract: A high intensity discharge lighting assembly capable of instant ON/OFF operation with a lamp housing having therein an HID lamp, an instant ON igniter circuit and lamp driver circuitry. The housing may have a screw in base or may be configured for fixed mounting on an open receptacle box. In one version, a non-replaceable HID lamp has leads permanently connected to the instant ON circuitry. In another version, the HID lamp has an integral base with pins which are plugged in to a socket provided in the housing.

Abstract: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Abstract: This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.

Abstract: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Abstract: There is disclosed a light source module comprising a high intensity discharge light source; optical elements including at least a reflector for redirecting and focusing the light emanating from said light source; and electronic elements for supplying said light source with voltage and current of a predetermined waveform and magnitude. The light source may have optical and/or electric parameters at least partially different from optical and/or electrical standard parameters of a light source of identical type. In order to provide a predetermined illuminating beam pattern compatible with the standard, the optical and/or electronic elements are adjusted to the optical and/or electrical parameters of said light source.

Abstract: A fluorescent lamp includes a light-transmissive glass envelope having an inner surface, means for providing an electric discharge to the interior of the glass envelope, a phosphor layer within the interior of the glass envelope and a discharge-sustaining fill gas and a mercury dose sealed inside the light-transmissive glass envelope. The light-transmissive glass envelope can comprise a light-transmissive mixed alkali glass envelope and the phosphor layer can comprise a phosphor layer of approximately three mg/cm2. A barrier layer of approximately 0.3 mg/cm2 or less of alumina can be applied to the inner surface of the light-transmissive glass envelope. The mercury dose can be present in an amount to provide a saturated mercury vapor pressure within the light-transmissive glass envelope throughout substantially the entire life of the lamp. The lamp can have an end-of-life mercury consumption value of approximately 0.63 mg or less, including 0.

Abstract: A light-source assembly includes a low-pressure fluorescent discharge tube arrangement having a cold spot temperature and radiating white light and at least one light-emitting diode radiating red light. An operating circuit supplies current to the discharge tube arrangement and the light-emitting diode. An outer envelope surrounds at least the discharge tube arrangement and provides a substantially homogenous light resulting from a mixture of the light radiated by the discharge tube arrangement and the light radiated by the light-emitting diode. A base mechanically and electrically connects at least the discharge tube arrangement in the outer envelope to a lamp-holder.

Abstract: A lamp having improved color quality scale is provided. The lamp has a light-transmissive envelope and a phosphor layer comprising a first phosphor and a second phosphor wherein the first phosphor has an emission band with a maximum between 590 nm and 640 nm and the second phosphor has an emission band with a maximum between 520 nm and 570 nm. The light generated by the phosphor layer, when the lamp is energized, has delta chroma values for all fifteen color samples of the color quality scale within select parameters. The delta chroma values are measured in the CIE LAB color space.

Abstract: A lamp having improved color quality scale is provided. The lamp has a light-transmissive envelope and a phosphor layer comprising a first phosphor and a second phosphor wherein the first phosphor has an emission band with a maximum between 590 nm and 670 nm and the second phosphor has an emission band with a maximum between 520 nm and 570 nm. The light generated by the phosphor layer, when the lamp is energized, has delta chroma values for fifteen color samples of the color quality scale within select parameters. The delta chroma values are measured in the CIE LAB color space.

Abstract: An ink composition for marking glass and ceramic surfaces, and for burning in said surfaces at an elevated temperature, the composition comprising the following components: 35-55% by weight pigment, 15-30% by weight lead-free frit, 20-45% by weight vehicle material, and the components constitute a total 100% by weight.

Abstract: This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.

Abstract: This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligand preferably an antagonist.

Abstract: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Abstract: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Abstract: The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Abstract: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Abstract: There is disclosed a light source module comprising a high intensity discharge light source; optical elements including at least a reflector for redirecting and focusing the light emanating from said light source; and electronic elements for supplying said light source with voltage and current of a predetermined waveform and magnitude. The light source may have optical and/or electric parameters at least partially different from optical and/or electrical standard parameters of a light source of identical type. In order to provide a predetermined illuminating beam pattern compatible with the standard, the optical and/or electronic elements are adjusted to the optical and/or electrical parameters of said light source.

Abstract: An ink composition for marking glass and ceramic surfaces, and for burning in said surfaces at an elevated temperature, the composition comprising the following components: 35-55% by weight pigment, 15-30% by weight lead-free frit, 20-45% by weight vehicle material, components constitute a total 100% by weight.

Abstract: The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containings them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and (III) and to the preparation thereof.

Abstract: Compounds of general formula (I), wherein R4 and R5 stand for hydrogen atom or form together an 1,3-butadienyl group, optionally substituted by a methylenedioxy group or one or more straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, hydroxy group or halogen atom; are strong adenosine A3 receptor ligands preferably antagonists.